GlassScriptPhysician profile
Richard P Erwin
NPI 1073545794
$1,260.66
in general payments reported to CMS, 2019-2025
26 companies · $17.14 in 2025
The $17.14 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $250 · 2021: $43.10 · 2022: $39.06 · 2023: $155 · 2025: $17.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $171.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $160.21 | 2022-2023 | |
| Ucb, INC. | $120.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $87.52 | 2019-2020 | |
| Lilly USA, LLC | $69.34 | 2019-2020 | |
| Sanofi Pasteur INC. | $68.23 | 2020-2023 | |
| Allergan, INC. | $67.57 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $66.61 | 2019 | |
| Medtronic USA, INC. | $65.02 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $62.98 | 2019-2020 | |
| Genzyme Corporation | $59.61 | 2019 | |
| Biogen, INC. | $59.02 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $48.35 | 2019-2025 | Koselugo |
| Takeda Pharmaceuticals U.S.A., INC. | $47.40 | 2020-2021 | |
| Emd Serono, INC. | $46.05 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $31.78 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.39 | 2019 | |
| Acadia Pharmaceuticals INC | $25.28 | 2019 | |
| Supernus Pharmaceuticals, INC. | $20.80 | 2019 | |
| Glaxosmithkline, LLC. | $19.89 | 2020 | |
| Genentech USA, INC. | $16.73 | 2019 | |
| Boston Scientific Corporation | $15.84 | 2019 | |
| Horizon Therapeutics Plc | $15.00 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.26 | 2019 | |
| Cranial Technologies, INC | $14.11 | 2022 | |
| Mallinckrodt Enterprises LLC | $13.87 | 2019 | |
| Assertio Therapeutics, INC. | $13.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Erwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.